TNP-ATP sodium

TNP-ATP, a derivative of ATP, acts as an antagonist to the purinergic P2Y1, P2X3, and P2X2/3 receptors, demonstrating selectivity by showing lower inhibitory concentrations (IC50 = 6, 0.9, 7 nM, respectively) compared to the P2X2, P2X4, and P2X7 receptors (IC50 = 2, 15.2, >30 µM, respectively) in HEK293 cells expressing these human receptors. It effectively diminishes acetic acid-induced calcium influx in 1321N1 cells targeting P2X3 and P2X2/3 receptors (IC50 = 100 and 62 nM, respectively) and alleviates pain in a mouse model of visceral pain (ED50 = 6.35 µmol/kg) . Moreover, TNP-ATP exhibits a notable fluorescence characteristic, with an emission peak at 547 nm after excitation at 403 nm, which enhances four-fold and shifts to 538 nm when bound to the insulin-degrading enzyme (IDE) .

O=P(OP([O-])([O-])=O)([O-])OP(OC[C@H]1O[C@@H](N2C=NC3=C(N)N=CN=C32)[C@@]4([H])[C@]1([H])OC5(C([N+]([O-])=O)=CC([N+]([O-])=O)C=C5[N+]([O-])=O)O4)([O-])=O.[Na+].[Na+].[Na+].[Na+]